

## AMENDMENTS TO THE CLAIMS

Claims 1-25 (canceled).

Claim <sup>1</sup>/<sub>26</sub> (currently amended) A method of producing activated T cells directed towards stratum corneum chymotryptic enzyme (SCCE) ~~in an individual with ovarian cancer, prostate cancer or breast cancer~~, comprising the steps of:

exposing dendritic cells to a human SCCE peptide selected from the group consisting of SEQ ID NOs: <sup>32, 33, 35, 36, 86</sup>~~31, 32, 33, 34, 35, 36, 80, 86, 99~~ or the human SCCE protein encoded by the DNA of SEQ ID NO: 30, thereby producing activated dendritic cells; and

exposing said activated dendritic cells to T cells, wherein said activated dendritic cells would present said SCCE peptide to said T cells, thereby producing activated T cells directed toward said SCCE ~~in the individual with ovarian cancer, prostate cancer or breast cancer.~~

Claims 27-29 (canceled).

Claim 30 (currently amended) ~~The~~ method of claim 26, wherein said dendritic cells are isolated from ~~the~~ <sup>an</sup> individual prior to said exposure to said

SCCE polypeptide, wherein said ~~activated~~ dendritic cells are reintroduced into said individual subsequent to said exposure.

Claim 31-39 (canceled).